髂总静脉支架治疗May-Thurner综合征后的妊娠结局
本研究回顾性分析8例因May-Thurner综合征行左髂总静脉支架置入后妊娠的女性患者,评估支架通畅性。所有支架在妊娠及产后均保持通畅,7例活产,1例死胎,1例妊娠期发生非阻塞性股静脉DVT但未影响支架。抗凝方案多样,提示治疗应个体化。
要点
- 妊娠未导致髂总静脉支架通畅性丧失。
- 抗凝和抗血小板方案差异大,低剂量阿司匹林或无需治疗对多数患者足够。
- 妊娠期非阻塞性DVT未影响支架通畅。
核心结论
- 8例May-Thurner综合征患者妊娠后髂总静脉支架均保持通畅。
研究设计与样本
- 回顾性病历复习,纳入8例18-45岁行左髂总静脉支架置入后妊娠的女性患者。
主要发现
- 8枚支架在妊娠及产后多普勒超声均显示通畅。
- 7例活产,1例死胎。
- 1例妊娠期发生左股静脉非阻塞性DVT,予治疗量依诺肝素,未影响支架。
- CEAP分级从妊娠至产后不变或改善。
- 支架置入平均年龄31±5岁,支架至妊娠平均间隔28±19个月。
关键数值与推荐
- 2例接受低剂量阿司匹林和预防量依诺肝素(1例有DVT史和因子V Leiden,1例近期生育治疗史)。
- 5例未抗凝,其中3例用低剂量阿司匹林,2例无抗血小板治疗。
临床怎么用
- 对于May-Thurner综合征支架置入后有生育需求的患者,妊娠期支架通畅性可维持,抗凝策略应个体化,多数可仅用低剂量阿司匹林或观察。
局限性
- 回顾性研究,样本量仅8例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For women with left common iliac vein compression (ie, May-Thurner syndrome) who undergo venous stenting and subsequently become pregnant, concerns have been raised regarding a possible compromise of stent patency due to compression from the gravid uterus and the hypercoagulability induced by pregnancy. Only a small body of literature exists on this subject, and limited management guidelines are available. The present study was designed to evaluate the safety of iliac vein stenting for May-Thurner syndrome (MTS) with subsequent pregnancy. METHODS: Female patients who had undergone common iliac vein stenting at our center who were aged 18 to 45 years and had subsequently become pregnant were identified. A retrospective medical record review of eight eligible patients was conducted, recording the demographics, procedural characteristics, and anticoagulation strategies. The primary outcome evaluated was stent patency. RESULTS: All eight patients had undergone left common iliac vein stenting for MTS. A total of eight stents were placed, and all demonstrated duplex ultrasound patency throughout pregnancy and postpartum. Seven patients delivered healthy pregnancies, and one experienced a stillbirth. The clinical CEAP (clinical, etiologic, anatomic, pathophysiologic) class remained unchanged or improved from pregnancy to postpartum for all patients. The average age at stent placement was 31 ± 5 years, and the average interval from stent placement to pregnancy was 28 ± 19 months. One patient developed nonobstructive deep vein thrombosis (DVT) of the left femoral vein during pregnancy and was treated with therapeutic enoxaparin. The nonobstructive DVT did not compromise the iliac vein stent. Two patients received low-dose aspirin and prophylactic doses of enoxaparin, one for a history of DVT and factor V Leiden and one for a recent history of fertility treatment. The five remaining patients received no anticoagulation, three received low-dose aspirin, and two received no antiplatelet therapy. CONCLUSIONS: Common iliac vein stent patency was not compromised by subsequent pregnancy in our eight patients with MTS. Furthermore, the stents remained patent throughout pregnancy in patients receiving a wide range of anticoagulation and antiplatelet treatments, suggesting that no uniform therapeutic threshold exists and treatment should be individualized. For most patients, low-dose aspirin alone or no treatment was adequate. This could have implications for counseling women who require intervention for MTS and are of child-bearing age.
引用
- Speranza G, Sadek M, Jacobowitz G, et al. Common iliac vein stenting for May-Thurner syndrome and subsequent pregnancy. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34438090. doi:10.1016/j.jvsv.2021.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。